(LEGN) Legend Biotech Corporation BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(LEGN) Legend Biotech Corporation Complete Analysis Pack
Actionable Strategy Starts Here
This Legend Biotech Corporation BCG Matrix is a strategic analysis tool that helps you assess the company’s products or business units across Stars, Cash Cows, Question Marks, and Dogs. The page already shows a real preview of the actual report content, so you can review the format and insight before buying. Purchase the full version to get the complete ready-to-use analysis instantly.
Stars
CARVYKTI 1 approved franchise
CARVYKTI, Legend Biotech Corporation's only marketed product, is a BCMA-directed CAR-T for relapsed or refractory multiple myeloma and the company's clear growth engine. In fiscal 2025, it remained the dominant revenue driver, with Legend Biotech Corporation reporting product revenue above $1 billion. As the only approved franchise, it sits in the Stars bucket: high growth, high share, and still the core value creator.
Multiple myeloma label expansion
CARVYKTI moved into earlier multiple myeloma settings, which expands Legend Biotech Corporation’s addressable pool and keeps this as a Stars business. In 2024, Johnson & Johnson reported CARVYKTI sales of $1.2 billion, up 93% year over year, showing strong early-line demand. The move from late-line to earlier use is a classic high-growth driver, with more eligible patients and deeper penetration ahead.
BCMA target leadership
BCMA remains one of the most validated targets in multiple myeloma, with 2 approved CAR-T therapies and a still-expanding treatment pool. Legend Biotech Corporation’s strongest share is here through CARVYKTI, which keeps winning use in a market that is still early in penetration. The target is a clear Star: high growth, strong clinical proof, and leading franchise momentum.
Janssen global commercialization
Legend Biotech’s partnership with Janssen Biotech is a clear Star because CARVYKTI gets global scale fast: Janssen co-develops and co-commercializes it across the U.S. and ex-U.S. markets, which matters in CAR-T where launch costs are high and utilization must rise fast. In 2025, CARVYKTI stayed Legend Biotech’s main revenue driver and remained the only approved BCMA CAR-T for multiple myeloma.
- Janssen expands market reach.
- Scale improves CAR-T economics.
Manufacturing scale-up
Legend Biotech Corporation’s CAR-T scale-up depends on tightly controlled cell-therapy manufacturing and cold-chain logistics, so added capacity can cut turnaround time and lift output. That matters because CARVYKTI already operates in a high-demand, high-complexity market, and each new slot or site still burns cash before volume catches up. In BCG terms, this is the “Stars” trade-off: growth first, margin later.
- More capacity means faster patient supply.
- Specialized logistics protect product quality.
- Scale-up raises cash burn before payback.
CARVYKTI Tops $1B as Legend Biotech’s Growth Engine
CARVYKTI is Legend Biotech Corporation’s Star: 2025 product revenue topped $1 billion, and it remains the company’s only marketed product. Expansion into earlier multiple myeloma lines should keep demand high, while the Janssen partnership supports global reach. High growth is clear, but scale-up still weighs on cash flow.
| Stars driver | Latest data |
|---|---|
| CARVYKTI revenue | Above $1B in 2025 |
| J&J 2024 sales | $1.2B, up 93% |
What is included in the product
Detailed Word Document
Legend Biotech BCG Matrix: stars, cash cows, question marks, and dogs mapped for investment, hold, or divest signals.
Editable Excel File
Legend Biotech BCG Matrix: clear quadrant view that pinpoints pain points fast for smarter portfolio decisions
Reference Sources
Provides a concise source trail for Legend Biotech, boosting credibility and helping decision-makers verify key assumptions fast.
Cash Cows
CARVYKTI commercial sales base
CARVYKTI is Legend Biotech Corporation’s only recurring revenue engine, and it already sells in relapsed/refractory multiple myeloma, an approved setting with repeat demand. The franchise delivered about $1.4 billion in 2024 global sales, so it is the closest thing to a cash cow in Legend Biotech Corporation’s BCG mix.
Janssen profit-share economics
Janssen profit-share economics turn CARVYKTI sales into recurring cash for Legend Biotech Corporation, with Janssen covering a large share of development and commercialization spend. J&J reported CARVYKTI sales of $963 million in 2024, up 91% year over year, which helps Legend scale cash flow as the franchise matures. That shared-cost model lowers Legend's funding burden and supports cash generation.
Reimbursement-backed demand
CAR-T for multiple myeloma is now part of standard care in major markets, with the U.S. expected to see about 36,110 new multiple myeloma cases in 2025. Reimbursement and growing center familiarity lower access friction, which supports steadier CARVYKTI demand. As uptake matures, higher-throughput treatment can lift margin quality over time.
Installed treatment-center network
Legend Biotech Corporation’s installed treatment-center network fits a cash-cow profile because CAR-T delivery only works through authorized centers with trained teams, so once a site is live, each extra patient adds less new cost. CARVYKTI sales rose to $963 million in 2024, showing how a built-out center base can keep scaling volume without the same level of new infrastructure spend.
- Authorized centers create a fixed, reusable delivery base.
- Training costs are front-loaded, then spread over volume.
- Incremental infusions are cheaper to serve.
- Higher volume can lift cash generation.
Single-franchise revenue concentration
Legend Biotech Corporation has no second approved product, so one franchise carries the business. FY2024 revenue was about $1.0 billion, driven almost entirely by CARVYKTI sales, which helps fund R&D and scale-up. That makes the base concentrated, but CARVYKTI’s growing demand can still act like a cash cow if uptake stays strong.
- Single approved franchise
- FY2024 revenue about $1.0 billion
- Funds operations and R&D
- Durable, but concentrated cash flow
CARVYKTI Powers Legend Biotech’s $1.4B Cash Engine
CARVYKTI is Legend Biotech Corporation’s only clear cash cow, with 2024 global sales of about $1.4 billion and Johnson & Johnson reporting $963 million, up 91% year over year. Its profit-share model and authorized-center network make revenue repeatable and keep serving costs lower as volume grows. With no second approved product, cash flow stays concentrated, but CARVYKTI still anchors funding for R&D and expansion.
| Metric | Value |
|---|---|
| 2024 global sales | $1.4 billion |
| J&J reported sales | $963 million |
| YoY growth | 91% |
| Approved revenue driver | CARVYKTI |
Get Your Copy
Legend Biotech Corporation Reference Sources
This preview shows the exact Legend Biotech Corporation BCG Matrix you’ll receive after purchase. No demo pages, no watermarks—just the complete, ready-to-use report. Once purchased, the same document is instantly available for download and practical use. It’s a clean, professional file built for strategic review.
Dogs
Preclinical solid-tumor programs
Legend Biotech Corporation’s preclinical solid-tumor programs are Dogs: they have no human efficacy data yet, while solid tumors make up about 90% of adult cancers and remain one of the hardest cell-therapy settings. With no clinical proof and no disclosed revenue contribution, these assets have low share and high technical risk versus CARVYKTI’s commercial focus in hematologic cancer.
Preclinical infectious-disease programs
Legend Biotech Corporation’s preclinical infectious-disease programs are still early and non-commercial, so they sit squarely in the Dogs bucket. There is no disclosed product revenue or market share tied to these assets, and the near-term return profile is weak. Until at least one program reaches clinical proof and a clear path to filing, capital tied here has low current payback.
No second marketed therapy
Beyond CARVYKTI, Legend Biotech has no other approved product, so most of its pipeline still lacks commercial pull. In FY2024, CARVYKTI drove nearly all revenue, with product sales of about $1.0 billion, showing heavy dependence on one asset. That kind of narrow base fits the "dog" label in BCG terms: low market breadth, weak diversification, and limited near-term cash generation.
Non-core exploratory discovery work
Legend Biotech Corporation still runs small cell-therapy discovery bets outside its core myeloma franchise. These programs are early-stage and usually generate little or no revenue, so they burn cash before they can prove value. That fits dog behavior in a BCG Matrix.
- Early-stage, high-burn work
- Outside core myeloma focus
- Low payoff visibility
With 2025 revenue still driven mainly by CARVYKTI, these exploratory projects look non-core and hard to scale.
No late-stage breadth outside MM
As of FY2025, Legend Biotech Corporation still leans on 1 commercial asset, Carvykti, while the disclosed pipeline remains mostly Phase 1/2 and preclinical. With no late-stage non-multiple myeloma program to seed a second revenue engine soon, the maturity gap is clear. Weak breadth and weak share outside MM keep this in "dogs" territory.
- 1 commercial asset; no near-term second base
- Pipeline is still early-stage heavy
- No late-stage depth outside MM
Legend Biotech’s Early Bets Burn Cash, Not Revenue
Legend Biotech Corporation’s Dogs are the early, non-commercial bets outside CARVYKTI: they have no disclosed revenue, no human efficacy proof, and weak near-term cash return. In FY2025, CARVYKTI still carried the business, with revenue near $1.0B, so these assets remain low-share, high-burn, and far from a second growth engine.
| Dog asset class | FY2025 signal | BCG read |
|---|---|---|
| Preclinical solid-tumor programs | No human data | Low share, high risk |
| Infectious-disease programs | No disclosed revenue | Non-core, weak payback |
| Other early pipeline | No late-stage depth | Cash burn before proof |
Question Marks
CD20 CAR-T for NHL/DLBCL
CD20 CAR-T for NHL/DLBCL sits in a large, growing market: diffuse large B-cell lymphoma makes up about 30% of non-Hodgkin lymphoma cases, and the U.S. sees roughly 80,000 new NHL cases a year. But the field is crowded, with several approved CAR-Ts already in market, so Legend Biotech Corporation’s share is still low. That makes this more of a high-potential question mark than a clear star.
CD22 CAR-T for ALL
CD22 CAR-T for acute lymphoblastic leukemia is a real growth option, but it is still early-stage. In relapsed/refractory ALL, CD22 is a clear target, and small trials have reported deep responses in heavily pretreated patients, but durability and safety are not yet proven at scale. That keeps this program in the Question Mark box for Legend Biotech Corporation.
CD19 CAR-T for B-cell malignancies
CD19 is a proven B-cell target with real scale: the U.S. now has multiple approved CD19 CAR-Ts, and the space keeps growing in relapsed/refractory lymphoma and leukemia. But it is also crowded, so Legend Biotech Corporation would need clearly better durability, safety, or access data to win share. Without a sharp edge, this stays a high-potential but hard-to-defend Question Mark.
Phase I gastric cancer candidate
Legend Biotech Corporation’s phase I gastric cancer candidate is still first-in-human, so it remains a Question Mark in the BCG Matrix. Gastric cancer is a large unmet-need market, with about 1.0 million new cases and 660,000 deaths worldwide each year, but share cannot be assigned until early safety and efficacy data read out.
- First-in-human stage.
- Big unmet-need market.
- Early data will set share.
Phase I T-cell lymphoma candidate
Legend Biotech Corporation’s Phase I T-cell lymphoma candidate is still an early bet, so it fits the Question Marks bucket. T-cell lymphoma is a small market, but it is clinically tough and has limited good options.
If early data show clear response and manageable safety, this asset could move into a niche growth story. The key test is whether its Phase I signals can justify later-stage spend.
- Early-stage, high-risk asset
- Small but hard-to-treat market
- Positive data could create niche value
Legend’s Early Bets: High Upside, High Uncertainty
Legend Biotech Corporation’s Question Marks are early, high-upside bets with weak current share. CD20 and CD19 face crowded CAR-T markets, while CD22 and T-cell lymphoma are still too early to prove durable wins. The Phase I gastric cancer program is first-in-human, so only early safety and response data can reprice it.
| Asset | Stage | Why Question Mark |
|---|---|---|
| CD20 CAR-T | Early | Crowded market |
| CD22 CAR-T | Early | Durability unproven |
| Gastric cancer | Phase I | First-in-human |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.